HighLife Website, Blog & Press Pages

HighLife Website, Blog & Press Pages - aVenture

HighLife - Library

highlifemedical.comCrawled Oct 4, 2026

Product

4 pages

Mitral Regurgitation, Our Focus/mitral-regurgitation
Mitral Regurgitation, Our Focus/fr/notre-priorite-la-regurgitation-mitrale
Trans-Septal Mitral Valve Replacement/our-tsmvr-solution
Trans-Septal Mitral Valve Replacement/fr/notre-solution-tsmvr

Press

5 pages

HighLife appoints Jose Calle Gordo as Chairman of the Board/highlife-appoints-jose-calle-gordo-as-chairman-of-the-board
HighLife SAS, a medtech company focused on the development of a unique trans-catheter mitral valve replacement (TMVR) system to treat patients suffering from
HighLife closes €12.3 million financing round led by Sofinnova Partners/highlife-closes-e12-3-million-financing-round-led-by-sofinnova-partners
HighLife SAS, an early-stage medtech company focused on the development of a unique trans-catheter mitral valve replacement (TMVR) system to treat patients
HighLife successfully initiates its clinical feasibility phase/highlife-successfully-initiates-its-clinical-feasibility-phase
HighLife SAS announced today the successful treatment of 5 consecutive patients in its early feasibility clinical phase. The first three cases
HighLife Successfully Initiates its Clinical Study in Europe/highlife-successfully-initiates-its-clinical-study-in-europe
HighLife SAS announced today the start of its European clinical study with the enrollment of the first 3 patients at major French university hospitals. This

About

2 pages

Our Mission and Expertise/who-we-are
Our Mission and Expertise/fr/nous-connaitre

Homepage

2 pages

Fr/fr
Stay informed about the latest developments from HighLife
Homepage/
HighLife is driven by a mission to deliver innovative treatment options to patients suffering from heart valve diseases.

Coverage

5 items

HighLife Raises $90+ Million to start its US Pivotal Study and accelerate Commercial Expansion in Europehighlifemedical.com/highlife-raises-90-million-to-start-its-us-pivotal-study-and-accelerate-commercial-expansion-in-europe/
HighLife SAS announces a financing round of more than $90 million to start its U.S. pivotal study and accelerate commercial expansion in Europe. The round is co-led by Andera Partners, Sofinnova Partners, Supernova Invest, and Merieux Equity Partners.
Sep 2026 · HighLifeNews article
HighLife Receives CE Mark Approval for Clarity Valve, the Next-Generation Valve for the HighLife TMVR Systemhighlifemedical.com/highlife-receives-ce-mark-approval-for-clarity-valve-the-next-generation-valve-for-the-highlife-tmvr-system/
HighLife SAS announced CE Mark approval for its Clarity Mitral Heart Valve, the next-generation valve for its TMVR System. The valve is purpose-built to mitigate LVOTO-related anatomical concerns while preserving the system’s established transfemoral valve-in-ring architecture.
Aug 2026 · HighLifeNews article
HighLife Receives CE Mark Approval for its TMVR Solutionhighlifemedical.com/highlife-receives-ce-mark-approval-for-its-tmvr-solution/
HighLife SAS receives CE Mark approval for its Transcatheter Mitral Valve Replacement (TMVR) System. The system is for adult patients with symptomatic moderate-severe or severe mitral regurgitation who are unsuitable for surgery or transcatheter edge-to-edge repair, and the approval begins a phased commercial introduction across Europe.
Jan 2026 · HighLifeNews article
HighLife granted US FDA Breakthrough Device Designation for its TMVR solutionhighlifemedical.com/highlife-granted-us-fda-breakthrough-device-designation-for-its-tmvr-solution/
HighLife SAS receives U.S. Food and Drug Administration Breakthrough Device designation for its trans-septal mitral valve replacement system for patients with moderate to severe mitral regurgitation. The designation is intended to ease the path to approval by enabling more frequent interactions with the FDA.
Apr 2025 · HighLifeNews article